期刊
EXPERT OPINION ON EMERGING DRUGS
卷 16, 期 3, 页码 587-596出版社
TAYLOR & FRANCIS LTD
DOI: 10.1517/14728214.2011.609168
关键词
5-HT receptor agonist; anorectic; appetite suppressant; glucagon-like peptide analogs; obesity; pancreatic lipase inhibitor; weight loss
资金
- Eli Lilly
- Amylin
- Pfizer
- Sanofi-Aventis
- Orexigen
- MetaProteomics
- Robert C and Veronica Atkins Foundation
Introduction: Obesity is a rapidly increasing global health problem. The rates of obesity have tripled over the past three decades and are predicted to rise even further. The need for safe and effective therapies is great and has gone unmet. Areas covered: This review will summarize the emerging pharmacological treatments for obesity. The research discussed includes Phase III and early-phase clinical trials as well as recently published data regarding emerging treatment therapies. Expert opinion: The new generation of anti-obesity drugs offers hope in the management of obesity, but no single agent is likely to be a panacea. Treatment of obesity will likely use multiple medications to achieve the desired result. Additionally, in light of the challenges faced by drug companies in order to gain FDA approval for an obesity therapy, the future approach may be to seek approval for obesity-related co-morbidities. This approach would enhance the ability of physicians to practice 'weight-centric' disease management.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据